Bio News

Amgen to Invest Additional $300 Million in Puerto Rico Plant, Increasing U.S. Manufacturing Capacity

Amgen will invest an additional $300 million in its biopharmaceutical plant in Puerto Rico to strengthen its U.S. supply chain. The expansion will bring total investment at the site to nearly $1 billion, and the facility is expected to become a manufacturing hub supplying medicin

2026-05-04

Latus Bio Raises $42 Million to Advance Huntington Disease Program Into Clinical Trials

Gene therapy startup Latus Bio has raised $42 million (approximately 60.9 billion won) and will begin clinical trials of a Huntington disease treatment. Latus is developing treatments for Huntington disease and CLN2 disease, a form of Batten disease, and expects to obtain early c

2026-05-04

UCB to Acquire Candide for 3.2 Trillion Won, Securing Autoimmune Bispecific Antibodies

UCB will acquire Candide Therapeutics in a transaction valued at 3.2 trillion won, including an upfront payment of 2.9 trillion won. The acquisition will give UCB four bispecific antibody pipeline programs, including the BCMA-targeted T-cell engager sizutamig. Sizutamig has been

2026-05-04

‘Blue Zones’ Trademark Sold for 113.1 Billion Won as Longevity Population in Original Region Plummets

The ‘Blue Zones’ brand has been sold for 113.1 billion won, but questions about its validity are growing as the longevity population in the original region declines sharply. A decrease in life expectancy among people born after 1930 and the possibility of recordkeeping errors hav

2026-05-04

AprilBio, Yuhan Corp. End Joint Cancer Drug Development Agreement After Four Years

AprilBio and Yuhan Corp. have mutually agreed to end their joint development agreement for SAFA-based cancer fusion proteins, signed in August 2022, about four years ahead of schedule. The termination reflects changes in the companies’ research and development strategies, and Apr

2026-05-04

In Diabetic Kidney Disease, Kidney Function Rapidly Worsens in a ‘B Cell–Rich’ Patient Group

A specific patient group has been identified in diabetic kidney disease, which occurs in approximately 40% of patients with diabetes, in which B cells form tertiary lymphoid structures and rapidly worsen kidney function. The research team used single-cell spatial transcriptomics

2026-05-04

Plastic-Degrading Bacteria Show 50% Higher Growth Rate After Five Cycles

Researchers at the National University of Singapore developed a gene-editing platform called “LySE” that improved the growth rate of plastic-degrading bacteria by 50.9% after five cycles. The technology uses bacteriophages to improve 40,000 base pairs of DNA at once—five times mo

2026-05-04

Colorectal Cancer–Causing Bacteria Survive by Manipulating Host Cells to “Produce” Oxygen

A mechanism has been identified by which the colorectal cancer–causing bacterium ETBF secretes a toxin to create an oxygen-rich environment. The toxin reduces oxygen consumption by host cells and generates lactate, which ETBF uses as an energy source. These findings provide a bas

2026-05-04

Zenkō Medical Named Sole Health Sector Winner of TIME’s TIME100 Impact Awards

Zenkō Medical was selected as the health sector winner of TIME’s TIME100 Impact Awards. Only five companies receive the award each year, and the company develops AI-based remote monitoring and disposable surgical systems. The technology shortens surgical turnover times to optimiz

2026-05-04

Zenko Medical Named to TIME’s ‘World’s 100 Most Influential Companies’ and Wins the Only Healthcare Award

Medical technology company Zenko Medical was named to TIME’s ‘World’s 100 Most Influential Companies’ and received the 2026 ‘TIME100 Healthcare Impact Award.’ The honor is awarded to only five companies each year, and Zenko Medical has developed biomimetic implants and AI-based r

2026-05-04